National Health (Originator Brand) Amendment Determination 2018 (No. 7) (PB 105 of 2018) (Cth)

PB 105 of 2018

National Health (Originator Brand) Amendment Determination 2018 (No. 7)

National Health Act 1953

I, SEAN LANE, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated     28 November 2018

______________________________________

SEAN LANE

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2018 (No. 7).

(2)     This Determination may also be cited as PB 105 of 2018.

1. Commencement

This Determination commences on 1 December 2018.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]                  Schedule 1 (after table item 229A)

insert:

229B Tocilizumab Actemra Actemra ACTPen Actemra Subcutaneous Injection